

Journal of Visualized Experiments

Production of germ-free fast-growing broilers from a commercial line for microbiota studies --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61148R1
Full Title:	Production of germ-free fast-growing broilers from a commercial line for microbiota studies
Section/Category:	JoVE Immunology and Infection
Keywords:	Chicken, Broiler, Germ-free, Microbiota, Ross PM3, Eggs
Corresponding Author:	Edouard Guitton INRA Centre Val de Loire Nouzilly, FRANCE
Corresponding Author's Institution:	INRA Centre Val de Loire
Corresponding Author E-Mail:	edouard.guitton@inra.fr
Order of Authors:	Edouard Guitton Arnaud Faurie Sébastien Lavillatte Thierry Chaumeil Pauline Gaboriaud Françoise Bussière Fabrice Laurent Sonia Lacroix-Lamandé Rodrigo Guariraba Catherine Schouler
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed. Please do not use abbreviations.	Nouzilly, 37380 France

TITLE:

Production of Germ-Free Fast-Growing Broilers from a Commercial Line for Microbiota Studies

AUTHORS AND AFFILIATIONS:

Edouard Guitton¹, Arnaud Faurie¹, Sebastien Lavillatte¹, Thierry Chaumeil¹, Pauline Gaboriaud²,
Françoise I. Bussière², Fabrice Laurent², Sonia Lacroix-Lamandé², Rodrigo Guabiraba², Catherine
Schouler²

¹INRAE, PFIE, UE-1277, Nouzilly, France.

²INRAE, ISP, Université de Tours, Nouzilly, France

Edouard Guitton: edouard.guitton@inrae.fr

Arnaud Faurie: arnaud.faurie@inrae.fr

Sébastien Lavillatte: sebastien.lavillatte@inrae.fr

Thierry Chaumeil: thierry.chaumeil@inrae.fr

Pauline Gaboriaud: pauline.gaboriaud@univ-tours.fr

Françoise I. Bussière: francoise.bussiere@inrae.fr

Fabrice Laurent: fabrice.laurent@inrae.fr

Sonia Lacroix-Lamandé: sonia.lamande@inrae.fr

Rodrigo Guabiraba: rodrigo.guabiraba-brito@inrae.fr

Catherine Schouler: catherine.schouler@inrae.fr

Corresponding author:

Edouard Guitton (edouard.guitton@inrae.fr)

KEYWORDS:

Chicken, Broiler, Germ-free, Microbiota, Ross PM3, Eggs

SUMMARY:

Here we describe a method for the generation of germ-free chicks from eggs of a commercial broiler line, the Ross PM3. This method can be adapted for the generation of germ-free animals from other poultry species.

ABSTRACT:

Studies of the gut microbiota contribution on the host physiology and immunocompetence are facilitated by the availability of germ-free animal models, which are considered as the gold standard. Nesting birds are ideal models for the production of germ-free animals since there is no need to raise their relatives under sterile conditions. Germ-free chickens are mainly generated from specific-pathogen-free (SPF) experimental lines, which are poorly representative of commercial chicken lines. The method proposed here allowed the production of germ-free chickens from the fast growing broiler line Ross PM3, commonly used by the poultry industry. Eggs were quickly collected after laying at a broiler breeder farm. They underwent a strict decontamination process from the collection to the introduction in a sterile egg hatching isolator. The chicks have been hatched and kept in these sterile isolators during the period

necessary to control their sterility. Originally developed for an experimental SPF white leghorn line, the present protocol has been adapted not only to the Ross PM3 broiler line but also to quails. It therefore represents a robust and readily adaptable procedure to other poultry species and nesting birds of economic, biological or ecological relevance.

INTRODUCTION:

There has been a dramatic increase in scientific and popular interest concerning the contribution of the intestinal microbiota to animal health. The microbiota, consisting of bacteria, viruses, fungi, and archaea that inhabit different niches in the animal's intestine, is implicated directly or indirectly in the regulation of inflammatory, infectious and metabolic diseases affecting not only mammalian species but also livestock, such as poultry¹. Several animal models were developed to better study the contribution of the gut microbiota to health and disease. For example, germ-free and gnotobiotic animals allow the study of the complete absence of microbes or of a known microbiota, respectively, on the physiopathology of infections^{2,3}. However, generating and maintaining these animals require specialized techniques and facilities, and the costs, labor, and skills required to maintain them limit their access to many researchers. Indeed, germ-free animals must be monitored regularly for possible contamination using a combination of bacteria cultivation methods, microscopy, serology, gross morphology, and sequencing-based detection techniques. Similar procedures also apply to other species, such as livestock, where animals are generally bigger and require larger facilities for their breeding and maintenance, which may hamper, to some extent, research on the microbiota.

Poultry, more specifically chickens, are the cornerstone of livestock production worldwide, with a flock population that may exceed 40 billion birds per year. It is the most important source of animal protein in the world (<http://www.fao.org/poultry-production-products/en/>). Moreover, there are no cultural or religious taboos associated to the rearing or consumption of chickens. The poultry gut microbiota is importantly involved in animal's growth, feed conversion ratio, immunity, pathogen resistance, among many other nutritional, physiological or pathological processes⁴. The generation of germ-free chickens is therefore indispensable to underscore the dialogue between the microbiota and its host⁴. Even if microbial communities inhabit the chicken oviduct⁵, the content of an egg freshly laid by a healthy hen is mostly free of microorganisms, the eggshell and membranes possessing mechanical barriers to avoid microorganism invasion⁴. In addition, chicks are easily raised in the absence of their relatives, which, unlike mammals, allows the production of germ-free animals without parental rearing under sterile conditions.

The experimental facility "Infectiology of Farm, Model and Wild Animals" (PFIE, UE-1277, Centre INRAE Val de Loire, Nouzilly, France, <https://doi.org/10.15454/1.5572352821559333e12>) is part of the French National Infrastructure Network EMERG'IN (<https://www.emergin.fr/>). PFIE has mastered the production of germ-free chickens to perform various experimental studies for more than 40 years^{7,8,9,10,11}. These animals were produced from specific pathogen-free (SPF) eggs from a white leghorn laying line raised in closed breeding since the 1970's. Mainly used for microbiological studies^{7,8,9}, germ-free birds are experiencing a resurgence of interest with questions such as the contribution of the gut microbiota to behavior¹³, nutrient utilization¹⁴, immune development¹⁵ and endocrine activity. Even if some studies have been published using

germ-free broiler lines¹⁶, these studies remain underrepresented compared to studies using experimental layer lines. The evolution of scientific questions towards the crosstalk between the microbiota and its host in poultry health and welfare has led us to adapt our historical protocol to produce germ-free broilers of the Ross PM3 line, the world's most utilized broiler chicken line.

PROTOCOL:

Animal care procedures were carried out in accordance with the guidelines set by the European Communities Council Directive (86/609/EEC) and by the French regulations on animal experimentation.

1. Isolator preparation

1.1. Insert the necessary materials into a rigid isolator under positive pressure: 50 mL tubes, 5, 10 and 25 mL plastic pipettes irradiated feed, autoclaved water and sterile sealed plastic containers.

1.2. Fill the transfer germicidal trap with a 2% quaternary ammonium solution.

1.3. Sterilize the isolator three times with formaldehyde vapor by using 60 mL of formalin (24% formaldehyde) added to 30 g of potassium permanganate per cubic meter (m³). Move the materials inside the isolator between each sterilization to ensure the sterilization of all contact surfaces.

1.4. Set the isolator temperature to 37 °C for at least 2 days before introducing the eggs. Set the hygrometer to 65-70% of relative humidity (RH) on the day of introduction.

2. Egg collection and incubation

2.1. Collect the eggs from farms selected on the basis of a good hatching rate of the laying hens (at least 80% at the peak of egg production) and their good sanitary status (i.e., absence of common poultry pathogens and absence of diseases within the flock). Visually select clean and flawless eggs on the treadmill.

2.2. Immediately decontaminate the egg surface by dipping them for 5 min in a 1.5% peracetic acid solution at room temperature.

2.3. Transport the eggs to the experimental facility using a box decontaminated with formaldehyde vapor.

2.4. Store the eggs for 24 hours at 4 °C. Repeat the decontamination process described in step 2.2, and place them in a hatching incubator (Day 0) for 19 days.

3. Hatching

133
134 3.1. On Day 19, verify the fertility, the viability (motility) and the embryo development by
135 candling them using a light egg candler under sterile conditions. Introduce only live-embryonated
136 eggs into the sterile hatching isolators.

137
138 3.2. Decontaminate the selected eggs by spraying 1.5% peracetic acid solution for 30 s or until
139 the entire surface of each egg is covered. Eggs will stay in contact with the spray for 16 min and
140 30 s during the transfer into isolators.

141
142 3.3. Transfer the eggs into the sterile hatching isolators and rinse them with sterile
143 demineralized water before placing them in the hatching space.

144
145 NOTE: Animals are hatched and reared in sterile isolators. They are fed ad libitum with a
146 commercial diet sterilized by gamma irradiation and watered with autoclaved tap water provided
147 by water dispensers.

148 149 **4. Bacteriologic status analysis**

150
151 4.1. One day after hatching, take a fecal sample directly from the rectum of different chicks
152 and pool them in a sterilized glass tube in order to make this sample representative of all animals
153 within a given isolator.

154
155 4.2. The fecal samples being more or less liquid, add an equivalent of 1 mL of stool to 9 mL of
156 thioglycolate broth with resazurin. Add the remaining fecal sample to 9 mL of brain heart infusion
157 broth (BHI) and incubate the tubes at 37 °C without shaking for 18 to 48 h. This will allow the
158 growth of a broad range of aerobic, facultative aerobic and nonfastidious anaerobic species.

159
160 NOTE: Thioglycolate broth with resazurin is intended for the detection of nonfastidious anaerobic
161 bacteria but it also enables the detection of aerobic bacteria. This medium complies with the
162 European, American, and Japanese pharmacopoeias for sterility testing^{18,19,20}.

163
164 4.3. Visually observe if any modification in the growth media occurs after 18 hours of
165 incubation. After 48 h, take a drop from the BHI fecal-broth media, place it on a glass slide and
166 observe under a microscope (40X magnification) for the absence or presence of bacteria.

167
168 4.4. If there is a suspicion on the presence of bacteria, take a sample from BHI culture and
169 seed it onto BHI agar plates. Incubate at 37 °C for 18 to 48 h.

170
171 4.5. If colonies are present, carry out high-throughput techniques such as MALDI-TOF mass
172 spectrometry for precise microbial identification.

173
174 NOTE: After 72 h, if the bacteriological analyses are negative, the animals are declared germ-free.

175 176 **REPRESENTATIVE RESULTS:**

Six runs of germ-free chicks' generation were conducted with Ross PM3 eggs coming from two different French farms (**Table 1**). A total of 853 eggs were collected and after two decontamination steps and 19 days of incubation, 86.40% were viable. 490 of these viable eggs underwent a third decontamination step and were introduced into various hatching isolators, for an average hatching rate of 79.80%. This represents a hatching rate of 68.94% compared to the initial number of eggs collected.

However, hatching results vary substantially according to the series carried out: from 41.67% to 88.16% of viable chicks compared to the number of eggs collected. These variations were also observed among the different hatches during the same experiment. Since not all isolators have been used for all runs, it is difficult to exclude an isolator-dependent effect. However, this batch effect was directly correlated with the age of the laying hens (**Figure 1**), where eggs coming from older hens were less viable.

The six runs were carried out using four different hatching isolators. After bacteriological control, the animals from 14 of the 16 isolators were confirmed to be germ-free. This corresponds to a success rate of 87.5%. The two remaining isolators were contaminated by a single environmental and nonpathogenic bacteria.

All animals used for the scientific experiments remained germ-free until the end of the studies, for at least three weeks after hatching.

FIGURE AND TABLE LEGENDS:

Figure 1: Effect of the hen's age on hatching rate

The present figure highlights the hatching rates observed based on the age of the laying hen flock, expressed in weeks of laying.

Table 1: Technical results of the different hatching experiments.

The present table highlights the results of the 6 series of germ-free hatching carried out: number of eggs collected, viability of the embryo at 19 days and viable hatched chicks in the various isolators.

DISCUSSION:

Several methods to generate germ-free chickens have been previously described^{7,21,22}. Simple methods, such as the one presented here, use different disinfectants to reduce bacterial load in the egg surface and in the isolators. The most commonly used disinfectants are mercuric chloride, quaternary ammonium, iodoform, sodium hypochlorite and chlorine dioxide solutions. The results are often satisfactory. However, despite the accessibility of these methods, few structures can apply the method and raise the animals in large scale, thus making the utilization of germ-free chickens a relatively rare approach, only used to address very specific scientific questions. The methods, materials and equipment described here allow a highly efficient hatching proportion of germ-free broilers, which remain healthy and sterile for at least 3 weeks (the duration of the scientific experiments to which they were produced).

The results show that the adaptation of the protocol to the production of germ-free chicks from eggs collected in commercial poultry farms is successful. Experience with SPF egg production reveals that hatching efficiency depends primarily on the age of the laying hens and on the quality of collected eggs. Both parameters were taken into consideration when farms were chosen and eggs collected. Using the same method, the average hatching rate of germ-free broilers is much better than that obtained in the last production of SPF laying hens at our facility (79% vs 35%), without affecting animal sterility (87% vs 83%). These differences may be associated to the genetic background of the birds (broilers versus layers) as well as to the quality of the eggshell, which is likely to be more fragile in the eggs of the SPF animals, kept in closed breeding for more than 40 years. Moreover, we also show that transportation of more than 2 h (from the farms to the experimental facility) does not affect hatching efficiency and quality.

Although the sterilization process used for hatching isolators and the protocol for egg decontamination were optimized, around 10% of the isolators were not germ-free. In order to understand the origin of the contamination, it is very important to carry out routine sterility control of the hatched isolators before egg introduction.

Concerning the birds' sterility status, we tried to apply methods that allow the growth of aerobic and nonfastidious anaerobic bacteria from fecal samples, thus assuring that we are detecting live, viable bacteria. These methods comply with international pharmacopeias for sterility testing and represent rapid, easy and cost-reduced techniques to be used routinely. However, molecular biology techniques such as 16S rRNA gene sequencing, although not giving information on bacteria viability, can be applied for the confirmation of the presence of noncultivable bacteria. Indeed, a recent study suggested that some bacteria of the maternal oviduct microbiota appear to be transferred to the embryo through the egg white, later constituting most of the embryo gut bacterial population. Moreover, another study suggests that part of the microbial colonizers harbored in early embryos were inherited from maternal hens, and the gut microbial abundance and diversity were later influenced by environmental factors and host genetics during development²³. However, the results of these studies are based on DNA sequence analysis, where a large number of those bacteria could be dead or not replicable in the egg white (greatly loaded with antimicrobial molecules). Thomas and collaborators¹⁶ performed sterility testing through the assessment of cultivable aerobic and facultative aerobic bacteria through fecal dropping on BHI plates, thus highlighting the efficiency of standard bacteriological methods for germ-free sterility control. Moreover, in the protocol proposed, we used growth monitoring in thioglycolate broth with resazurin to be able to detect the growth of nonfastidious anaerobic bacteria.

Already used for the production of germ-free quails and chickens, the protocol is adaptable to the production of germ-free animals from most nesting birds and offers perspectives for the study of microbiota contribution on the physiology of these animals. Besides the use of this model to investigate host-microbiota mutual interactions in the poultry gut, it could also be useful for applied research. For example, it could be used to assess safety and efficacy of probiotics derived from chicken gut commensal microorganisms to improve animal's health and robustness.

ACKNOWLEDGMENTS:

The authors are grateful to the breeders and the society Boyé accoupage (La Boissière en Gâtine, France) for the supply of fertilized eggs. This study was conducted under the auspices of the research consortium APR-IA "INTEGRITY" (2017-2019), which was funded by the Région Centre Val de Loire, France.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Shang, Y., Kumar, S., Oakley, B., Kim, W.K. Chicken gut microbiota: importance and detection technology. *Frontiers in Veterinary Science*. **23**, 5-254 (2018).
2. Grover, M., Kashyap, P.C. Germ-free mice as a model to study effect of gut microbiota on host physiology. *Neurogastroenterology & Motility*. **26** (6), 745-8 (2014).
3. Umesaki, Y. Use of gnotobiotic mice to identify and characterize key microbes responsible for the development of the intestinal immune system. *Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences*. **90** (9), 313-32 (2014).
4. Carrasco, J.M., Casanova, N.A., Fernández, M.E. Microbiota, gut health and chicken productivity: what is the Connection? *Miyakawa. Microorganisms*. **7** (10), 374 (2019).
5. Lee, S. et al. Characterization of microbial communities in the chicken oviduct and the origin of chicken embryo gut microbiota. *International Journal of Scientific Reports*. **9** (1), 6838 (2019).
6. Hincke, M.T. et al. Dynamics of structural barriers and innate immune components during incubation of the avian egg: critical interplay between autonomous embryonic development and maternal anticipation. *Journal of Innate Immunity*. **11** (2), 111-124 (2019).
7. Le Bars, J. Demonstration of a protocol for obtaining germ-free chickens. *Annals of Veterinary Research*. **7**, 383-96 (1976).
8. Lafont, J.P. et al. Experimental study of some factors limiting 'competitive exclusion' of *Salmonella* in chickens. *Research in Veterinary Science*. **34** (1), 16-20 (1983).
9. Brée, A., Dho, M., Lafont, J.P. Comparative infectivity for axenic and specific-pathogen-free chickens of O2 *Escherichia coli* strains with or without virulence factors. *Avian Diseases*. **33** (1), 134-9 (1989).
10. Dozois, C.M. et al. Bacterial colonization and in vivo expression of F1 (type 1) fimbrial antigens in chickens experimentally infected with pathogenic *Escherichia coli*. *Avian Diseases*. **38** (2), 231-9 (1994).
11. Schouler, C., Taki, A., Chouikha, I., Moulin-Schouleur, M., Gilot, P. A genomic island of an extraintestinal pathogenic *Escherichia coli* strain enables the metabolism of fructooligosaccharides, which improves intestinal colonization. *Journal of Bacteriology*. **191** (1), 388-93 (2009).
12. Porcheron, G., Chanteloup, N., Trottereau, A., Brée, A., Schouler, C. Effect of fructooligosaccharide metabolism on chicken colonization by an extra-intestinal pathogenic *Escherichia coli* strain. *PLoS One*. **7** (4), e35475 (2012).
13. Krami, N. et al. Effects of a gut microbiota transfer on emotional reactivity in Japanese

309 quails (*Coturnix japonica*). *Journal of Experimental Biology*. **222** (2019).

310 14. Stanley, D. et al. Intestinal microbiota associated with differential feed conversion
 311 efficiency in chickens. *Applied microbiology and biotechnology*. **96**, 1361-1369 (2012).

312 15. Han, Z. et al. Influence of the gut microbiota composition on *Campylobacter jejuni*
 313 colonization in chickens. *Infection and Immunity*. **85** (11), e0038017 (2017).

314 16. Thomas, M. et al. Gut microbial dynamics during conventionalization of germfree chicken.
 315 *mSphere*. **4** (2), e00035-19 (2019).

316 17. Langhout, D.J., Schutte, J.B., de Jong, J., Sloetjes, H., Verstegen, M.W., Tamminga, S. Effect
 317 of viscosity on digestion of nutrients in conventional and germ-free chicks. *British Journal of*
 318 *Nutrition*. **83** (5), 533-40 (2000).

319 18. European Pharmacopoeia (Ph. Eur.): Supplement 6.3 (official in January 2009), Sterility
 320 (reference 01/2009:20601).


321 19. Japanese Pharmacopoeia (JP): The 4.06 Sterility Test as it appeared in the partial revision
 322 of the JP 15th edition (made official March 31, 2009, by the Ministry of Health, Labour and
 323 Welfare Ministerial Notification No. 190).

324 20. United States Pharmacopeia (USP): <71> Sterility Tests as presented in Pharmacopeial
 325 Forum, Volume 34(6), Interim Revision Announcement No. 6, December 1, 2008, official on May
 326 1, 2009

327 21. Harrison, G.F. Production of germ-free chicks: a comparison of the hatchability of eggs
 328 sterilized externally by different methods. *Laboratory Animals*. **3** (1), 51–59 (1969).

329 22. Yokota, H., Furuse, M., Okumura, J., Iwao Task, I. A simple method for production and
 330 rearing of the germ-free Chick. *J-STAGE home Nihon Chikusan Gakkaiho*. **55** (8) (1984).

331 23. Ding, J. et al. Inheritance and establishment of gut microbiota in chickens. *Frontiers in*
 332 *Microbiology*. **8**, 1967 (2017).



	Collected eggs	D19 viable eggs	D19 viable eggs/collect ed eggs	Eggs tranfered into isolator 1	Eggs tranfered into isolator 2	Eggs tranfered into isolator 3
Run 1	101	93	92.08%	23	24	-
Run 2	130	117	90.00%	25	25	25
Run 3	132	97	73.48%	26	-	26
Run 4	130	116	89.23%	36	35	-
Run 5	180	148	82.22%	30	30	30
Run 6	180	166	92.22%	-	40	40
Total	853	737	86.40%	140	154	121

Eggs tranfered into isolator 4	total of transferred eggs	viable chicks hatched into isolator 1	viable chicks hatched into isolator 2	viable chicks hatched into isolator 3	viable chicks hatched into isolator 4	total of viable hatched chicks
-	47	22	23	-	-	45
	75	20	24	18	-	62
45	97	14	-	13	28*	27
-	71	33	34	-	-	67
30	120	26*	25	17	24	66
-	80	-	35	35	-	70
75	490	89	141	83	24	337

viable hatched/transferred eggs isolator1	viable hatched/transferred eggs isolator2	viable hatched/transferred eggs isolator3	viable hatched/transferred eggs isolator4	viable hatched/transferred eggs global
95.65%	95.83%			95.74%
80.00%	96.00%	72.00%		82.67%
53.85%		50.00%	62.22%	56.70%
91.67%	97.14%			94.37%
86.67%	83.33%	56.67%	80.00%	76.67%
86.67%	87.50%	87.50%		87.50%
82.14%	91.56%	68.60%	69.33%	79.80%

Name of Material/ Equipment	Company	Catalog Number
2 mL sterile plastic pipettes	Starsted	86.1252.001
50 mL tubes	Falcon	
BHI agar plates	Thermo fisher diagnostic	PO1198A
Brain Heart Infusion broth	Thermo fisher diagnostic	CM1135
Glass tubes with 9 mL BHI broth		
Glass tubes with 9 mL thioglycolate broth with resazurin		
Hatching incubator	Fieme	MG 576
Incubator	Memmert	
Irradiated feed	Safe	U8983G10R
Isolators		
Microbiological safety cabinet	thermon electron corporation	
Microscope Visiscope series 300	VWR	
Pipette aid	Drummond	
Plastic pipettes		
Sterile sealed boxes	Tuperware	
Sterilized glass tube		
Thioglycolate Broth with Resazurin	Merck	90404-500G
Water bath	Fisher scientific	

Comments/Description

home made and sterilized by autoclaving

home made and sterilized by autoclaving

for bacteriological culture, 37 °C

40 kG irradiated

home made. 1 m³ rigid isolator under positive pressure

model: Hera Safe

diameter

"sovirel"

model: polystat 36, used to incubate 10 min at 100 °C the glass tubes with 9 mL thioglycolate broth with resazurin in order to regenerate the medium

Reference: JoVE61148 "Production of germ-free fast-growing broilers from a commercial line for microbiota studies"

Dear Dr. Steindel,

We appreciate the editorial and reviewers' helpful suggestions, which will certainly improve the quality of our manuscript. Below you will find a point-by-point reply to editorial and reviewers' comments. We hope our manuscript is now suitable for publication and video production.

Editorial comments:

General:

1. *Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.*

We have thoroughly proofread the manuscript.

2. *Please include email addresses for all co-authors in the manuscript itself.*

E-mail addresses were included.

3. *Please include at least 6 key words or phrases.*

We have added 2 more keywords to the revised version.

4. *JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please limit the use of commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.*

For example: Pyrex

We removed all commercial language.

Protocol:

1. *Please include an ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.*

Line 91: An ethical statement was added to the beginning of the Protocol section.

2. *For each protocol step/substep, please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. If revisions cause a step to have more than 2-3 actions and 4 sentences per step, please split into separate steps or substeps.*

We tried to make all steps clearer.

Specific Protocol steps:

1. 2.1: *It's unclear what exactly "on the basis of their hatching rate and health status" means.*

Line 109: We have clarified this sentence in the text. To be clearer, we propose the following modification: "Collect the eggs from farms selected on the basis of a successful hatching rate of the

laying hens at least 80 % at the peak of egg production) and their good sanitary status (i.e. absence of common poultry pathogens and absence of diseases within the flock).

Figures/Tables:

1. Table 1: Please upload as a .xls/.xlsx file. Please use periods instead of commas for decimals.

We performed the modifications requested.

References:

1. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage – LastPage (YEAR).] For more than 6 authors, list only the first author then et al.

2. Please do not abbreviate journal titles.

We have carefully checked each reference

Table of Materials:

1. Please ensure the Table of Materials has information on all materials and equipment used, especially those mentioned in the Protocol.

We have provided a Table of Materials in details.

Reviewers' comments:

Reviewer #1:

The manuscript JoVE61148 entitled "Production of germ-free fast-growing broilers from a commercial line for microbiota studies" reports on a procedure to produce germ-free fast-growing broilers from a commercial line. The manuscript deals with a relevant issue in broiler research and production.

Some indications to improve the manuscript are given below.

Specific points:

line 113 Reads: Bacteriologic status analysis. Comment: Why molecular biology techniques (qualitative and quantitative PCR, metagenomic sequencing, etc.) are not used here? They are much more sensitive, precise and powerful than traditional cultivation methods. Is there any official regulation on the procedures to be used to produce germ-free birds?

We understand this reviewer's concern. However, the traditional cultivation methods we used allow the detection of several aerobic and anaerobic bacteria within a few days. For sure, molecular biology techniques are of interest, although they will essentially lead to the determination of the presence (or absence) of bacterial DNA without giving any indication on whether bacteria are viable or not. Nevertheless, we added new information on this topic to the protocol. Please also see the reply to Reviewer #2 for more details.

line 162 Comment: Discussion. This section should be enriched with aspects such as the improvements respect to the previous method, limitations, etc. Also some more information on microbiological aspects would be welcome.

We tried to improve this section as per this reviewer's suggestion.

line 193 Reads: to improve animal's health and Comment: incomplete

line 239:We have clarified this part of the manuscript.

lines: 256-258. Comment: Is not there any more recent reference on this issue?

We preferred to use the seminal references as the techniques utilized in these studies remain relevant to the production of germ-free birds.

Reviewer #2:

What is the difference between the SPF and commercial broilers germfree protocols? Should consider combining the two methods and highly places where procedures should be done differently. For example, commercial broiler eggs are collected from the field and transported to the lab while SPF eggs are obtained locally. Are there more differences?

The differences mainly rely on the rapidity and efficiency of the disinfection and transportation techniques while recovering eggs from environments other than a BSL2 hatching room. We believe we made clear that these steps are the main (and crucial) differences between the two protocols.

Lines 60-62. No proof that their chickens are germ free (see a detailed comment below)

Please see detailed information on the reply to Reviewer #2.

Line 81: Should specify the isolator model used and also described the basic characteristics of the isolator: is it negative pressure, etc

Characteristics were added. However, we are not allowed to cite the isolator model as per Journal's instructions (i.e. "avoid commercial language").

Line 87: Should clarify in the protocol why are the materials being moved.

Line 103: We have now clarified this information.

Line 89: spelling: hygrometer

Corrected.

Lines 93-94: suggested correction:"...egg surface by dipping them in a solution of peracetic acid (1.5% Divosan Plus VT53, JohnsonDiversey, France) for five minutes at room..."

Line 113:Corrected. Thank you for the suggestion.

Lines 97-99: Store the eggs for 24 hours at 4°C, repeat the decontamination process described in step 2.2, and place them in a hatching incubator (Day 0) for 19 days. [no need to restate the hatching incubator conditions - they are stated in step 1.4]

Line117: Modified as per this reviewer's suggestion.

Line 103: the word "different" is not necessary

Line 118: Modified as per this reviewer's suggestion.

Lines 104-105: spraying "for 30 seconds" is not a clear instruction. Consider using a different kind of description, for example, spraying until the entire surface of each egg is covered with disinfectant.

Line123-125: Modified as per this reviewer's suggestion.

Lines 114-119: replace the word "stool" with "feces" or "fecal".

Line 134-136: Modified as per this reviewer's suggestion.

Line 130: This reviewer disagrees with this statement because: 1) Only aerobic bacteria are tested. Besides, only a small percentage of bacteria are culturable.

We partly disagree with this reviewer's comment. Thioglycollate broth with resazurin is intended for the detection of anaerobic bacteria but it also enables the detection of aerobic bacteria (BREWER J.M. - Clear liquid mediums for the « aerobic » cultivation of anaerobes - J.A.M.A. , 1940, Vol. 115, p. 598-600). The broth contains a mixture of peptones, which encourage the growth of most bacteria. The reducing agents (L-cystine and thioglycolic acid) and the yeast extract included in the medium favour the growth of anaerobic bacteria. The redox indicator (resazurin) reveals the presence of oxygen (pink to mauve colour). However, as growth depends on the requirements of each individual microorganism, it is therefore possible that certain strains, which have specific requirements, (substrate, temperature, incubation conditions etc.), may not grow. Finally, this medium complies with the European, American, and Japanese pharmacopoeias for sterility testing. We now added this information to the protocol.

2) Surface decontamination of eggs does not mean elimination of bacteria. The reviewer disagrees with the authors' argument that "The content of an egg freshly laid by a healthy hen is free of microorganisms, the eggshell and membranes possessing mechanical barriers to avoid microorganism invasion". It is established that eggs are not formed in a sterile reproductive system [see Lee et al, Sci Rep. 2019 May 2;9(1):6838.].

The authors agreed that some microorganisms could be embedded within the egg during oviposition. However, to face bacterial growth that could impair embryo viability, embryonated eggs possess many weapons such as antimicrobial molecules (lysozyme, defensins, ovotransferrin) (Hincke et al., J. Innate Immun. 2018). These molecules may also contribute to limit the growth of certain bacteria derived from the hens and present in the egg white, as shown by Lee et al. (Sci Rep. 2019).

Thus, without treatment with antibiotics during the first few days of life, it might be impossible to raise truly germfree chickens. The authors should address this in the Discussion. This reviewer is aware of the study by Thomas et al (mSphere. 2019 Mar 27;4(2). pii: e00035-19) which similarly declared chickens to be germfree based on the absence of viable bacteria.

In Thomas et al. (mSphere, 2019), the germ-free status of the chicks was only checked through fecal dropping on BHI plates. We agree this technique will only allow the detection of aerobic and facultative aerobe bacteria. This is why we used thioglycollate broth with resazurin to be able to detect the growth of nonfastidious anaerobic bacteria. We added this information to the protocol.

Curiously, that study did not report 16S rRNA gene data from uninoculated "germfree" chickens which obviously should have been included as controls. Hence, while the current work in this study and other published studies are encouraging, culture-independent methods such as 16S rRNA gene sequencing should be the gold standard for sterility confirmation.

Although we agree with the reviewer on the relevance of culture-independent methods, 16S rRNA gene sequencing, for example, will only lead to the determination of the presence (or absence) of bacterial DNA without giving any indication on bacteria viability. Thus, bacterial culture (as a first intention) and culture-independent methods can be used in tandem to address different questions concerning sterility.

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Production of germ-free fast-growing broilers from a commercial line for microbiota studies

Author(s):

Guillon E., Faurie A., Lavillatte S., Chaumeil T., Gaboriaud P., Bussière F., Laurent F.,
Lacroix-Lamandé S., Guabiraba R., Schouler C.

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

Edouard GUITTON